By Ian Walker

Haleon said that organic revenue grew 5% in the third quarter on pricing and positive volume mix, and backed its full-year guidance.

The consumer-healthcare business--which houses Sensodyne toothpaste and Aquafresh mouthwash as well as over-the-counter medicines Panadol and Advil--said Thursday that revenue for the quarter was 2.80 billion pounds ($3.40 billion) compared with GBP2.89 billion for the comparable period a year earlier and a company-compiled analyst consensus of GBP2.83 billion.

Organic revenue consensus was for growth of 5.1%.

Pretax profit for the quarter was GBP496 million compared with GBP495 million.

Adjusted earnings before interest and taxes--a company preferred metric which strips out exceptional and other on-off items--was GBP689 million compared with GBP725 million and a consensus of GBP694 million.

The company reiterated that organic revenue growth for 2023 is expected to be 7% to 8% while adjusted operating profit is expected to grow between 9% and 11% at constant currency for the year.

GSK has a 7.4% stake in Haleon--which was spun out of GSK and Pfizer's consumer healthcare business--having recently reduced it from 10.3%, while U.S. pharma giant Pfizer holds 32%.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

November 02, 2023 03:41 ET (07:41 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Haleon (LSE:HLN)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Haleon
Grafico Azioni Haleon (LSE:HLN)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Haleon